Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Aclarion, Inc.

The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.

Tech Coast Angels

Aclarion

Chronic low back pain is a life-changing condition that prevents many individuals from living full and healthy lives. And finding the right treatment option for each patient’s unique situation can take months, if not years, to find. 
 
With Nociscan, patient-specific biomarker data helps physicians quickly assess which discs are potentially the source of a patient’s pain so physicians can optimize treatment strategies and help patients get back to an active, pain-free life.
 
Patients around the world are already experiencing the benefits of Nociscan. To learn more about how Nociscan can help you or a loved one, visit www.aclarion.com.
 
#ACON #ACONW #spine #nasdaq #lowbackpain

Last weekend at ISASS 2023, Leslie Wilson presented a cost-effectiveness abstract overviewing the initial findings of the EVAL study (Economic Value Analysis of Low back pain). The study found that Nociscan demonstrated statistical dominance over provocative discography with the potential to save the US healthcare system $283M to $441M annually. Read the full release here. https://lnkd.in/gMNt2uMw

#ACON #ACONW #nasdaq #lowbackpain #nociscan #spinesurgery #ISASS

New and compelling healthcare economics data from the EVAL Study (Economic Value Analysis of Low back pain Study) will be presented this week at ISASS 2023 in San Francisco! 

Join Aclarion on Saturday, June 3 in Salon 13-15 at 10:34 am to learn about the initial findings of this pivotal economic analysis of the Nociscan solution for the treatment of low back pain. 

Presentation title: Cost-effectiveness of novel, non-invasive diagnostic test for chronic low back pain. 
Presenter: Leslie Wilson, Professor at UCSF. 

#ACON #ACONW #ISASS23 #lowbackpain #spinesurgery #nasdaq

Aclarion announced today their commercial agreement with the prestigious London Clinic and London Spine Clinic. The London Clinic is one of the UK’s largest and most renowned independent hospitals. Based in the heart of London’s medical district, the Clinic has a heritage of investing in the latest technologies and providing exceptional medical care through state-of-the-art facilities.

“The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options available to them.  Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis,” said John Sutcliffe MD, Neurosurgeon, and Founder of London Spine Clinic.

Read the full announcement here. https://lnkd.in/gAmfkDQT

#ACON #ACONW #nasdaq #londonspineclinic #londonclinic #nociscan #spinesurgery

Aclarion’s CEO Brent Ness was recently interviewed by Proactive about the value of the Nociscan solution when treating patients with chronic low back pain and the corporate milestones that the company has recently achieved. Watch the full interview here. https://lnkd.in/gzEPAhkm

#ACON #ACONW #nasdaq #nociscan #lowbackpain #spine #spinesurgery

Wonderful Aclarion symposium today at SpineWeek in Melbourne. Standing room only to hear spine experts Sigurd Berven MD and Jeff Lotz PhD discuss the value of the Nociscan solution in addressing the question of Where’s the Pain? The clinical and economic data are clear: Nociscan improves clinical outcomes and has the potential to significantly reduce the cost of care. Visit www.aclarion.com to learn how you can bring Nociscan to your spine center. 

#ACON #ACONW #nasdaq #spineweek #painmanagement #pain #nociscan #spinesurgery

Attending SpineWeek in Melbourne next week? If so, join us Tuesday, May 2 for a sponsored symposium, Where’s The Pain?, led by renowned spine experts Sigurd Berven, MD and Jeff Lotz, PhD. New clinical and economic data will be presented demonstrating the value of the Nociscan solution to aid in the treatment of chronic low back pain. Hope to see you there.

#ACON #ACONW #nociscan #spineweek #spine #nasdaq #pain #painmanagement

We’re excited to announce the publication of two-year durability data which demonstrates improved surgical outcomes for discogenic low back pain (DLBP) surgeries at chemically painful lumbar discs identified by Nociscan. Success rates at 2 years for DLBP low back pain surgeries was 85% for patients whose treatment strategy was consistent with Nociscan-identified discs, a 22 percentage point improvement over patients whose treatment strategy was inconsistent with Nociscan-identified discs. (85% vs. 63%; p=0.07). Access the full article at https://lnkd.in/dCREgnkE

#ACON #ACONW #spinesurgery #nociscan #lowbackpain

Great debate last Friday at the 2023 Annual AANS/CNS Spine Summit between Juan Uribe, MD and Christopher Ames, MD on the role of AI and ML in spine surgery. Important topics raised by both sides and clearly, the future of spine care will be influenced by this growing field. 

Thank you, Dr. Uribe and Dr. Ames, for your continued commitment to advancing care for patients suffering from chronic low back pain.

#ACON #ACONW #spine #AI #machinelearning

Great topic for a debate! Looking forward to tomorrow's discussion.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-4.02M -	-4.64M 15.33%	-4.95M 6.80%	-7.61M 53.64%	-4.91M 35.42%
depreciation and amortization	178.21K -	196.28K 10.14%	189.37K 3.52%	193.62K 2.24%	162.67K 15.99%
deferred income tax	-649.11K -		-343.12K -		-219.14K -
stock based compensation	28.04K -	26.13K 6.81%	177.49K 579.20%	1.29M 626.05%	456.00K 64.61%
change in working capital	-358.23K -	538.27K 250.26%	676.29K 25.64%	805.30K 19.08%	219.14K 72.79%
accounts receivables	-14.70K -	-7.81K 46.87%	16.22K 307.79%	-12.29K 175.76%	-1.49K 87.87%
inventory
accounts payables	-249.96K -	342.23K 236.92%	199.60K 41.67%	-603.10K 402.15%	220.63K 136.58%
other working capital	-93.58K -	203.85K 317.84%	460.46K 125.88%	1.42M 208.54%	-219.14K 115.43%
other non cash items	649.11K -	79.13K 87.81%	1.90M 2,301.66%	3.79K 99.80%	645.76K 16,933.92%
net cash provided by operating activities	-4.17M -	-3.80M 9.01%	-2.35M 38.08%	-5.31M 126.14%	-3.65M 31.37%
investments in property plant and equipment	-267.21K -	-179.03K 33.00%	-152.00K 15.09%	-208.87K 37.41%
acquisitions net				1K -
purchases of investments
sales maturities of investments
other investing activites					-119.52K -
net cash used for investing activites	-267.21K -	-179.03K 33.00%	-152.00K 15.09%	-207.87K 36.75%	-119.52K 42.50%
debt repayment	-515.55K -	-1.86M 261.03%	-2.94M 57.93%	-2M 31.96%
common stock issued	1.80K -			8.55M -	1K 99.99%
common stock repurchased
dividends paid				-415.52K -
other financing activites	3.46M -	5.72M 65.24%	2.94M 48.63%	415.52K 85.86%	3.31M 697.48%
net cash used provided by financing activities	2.95M -	3.86M 30.92%	2.94M 23.87%	6.55M 122.91%	3.31M 49.41%
effect of forex changes on cash				-1 -
net change in cash	-1.49M -	-113.18K 92.40%	437.55K 486.59%	1.03M 135.47%	-451.74K 143.85%
cash at beginning of period	1.62M -	128.16K 92.07%	14.98K 88.31%	452.53K 2,920.09%	1.48M 227.67%
cash at end of period	128.16K -	14.98K 88.31%	452.53K 2,920.09%	1.48M 227.67%	1.03M 30.47%
operating cash flow	-4.17M -	-3.80M 9.01%	-2.35M 38.08%	-5.31M 126.14%	-3.65M 31.37%
capital expenditure	-267.21K -	-179.03K 33.00%	-152.00K 15.09%	-208.87K 37.41%
free cash flow	-4.44M -	-3.97M 10.45%	-2.50M 37.05%	-5.52M 120.75%	-3.65M 33.97%

COM:ACLARION

Aclarion, Inc.

Last Close

0.18

22/11 21:00

Market Cap

2.49M

Beta: -

Volume Today

124.21K

Avg: -

Preview